Adma Biologics Inc IPO-Jahr
Was ist das IPO-Jahr von Adma Biologics Inc?
IPO-Jahr von Adma Biologics Inc ist 2013
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc
Was macht Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Unternehmen mit ipo-jahr ähnlich Adma Biologics Inc
- AMG Capital Trust II hat IPO-Jahr von 2012
- Live Nation Entertainment hat IPO-Jahr von 2012
- MGM Resorts International hat IPO-Jahr von 2012
- EnerSpar hat IPO-Jahr von 2012
- The Western Union hat IPO-Jahr von 2012
- Wameja hat IPO-Jahr von 2012
- Adma Biologics Inc hat IPO-Jahr von 2013
- Opus Bank hat IPO-Jahr von 2014
- Recro Pharma Inc hat IPO-Jahr von 2014
- Radius Recycling hat IPO-Jahr von 2014
- Progenity hat IPO-Jahr von 2014
- Axalta Coating Systems Ltd hat IPO-Jahr von 2014
- Anevia SA hat IPO-Jahr von 2014